On February 17, the 2022 “Digital Health Companies China 50” list was released at the “2023 MIT Technology Review China Future Health” Summit. As one of the most important benchmarks of digital health, the list consists of 50 outstanding healthcare science and technology companies from six major fields that affect digital health. Among the 50, five promising AI-driven biotech companies including Evergreen Therapeutics, Insilico Medicine, XtalPi were recognized by virtue of their outstanding achievements in the field of digitalization of pharmaceutical R&D.
Professor Mohamad Sawan (Fellow of the Canadian Academy of Engineering) address the forum
As a US-China based AI-driven biopharmaceutical company, Evergreen Therapeutics is pioneering and highly differentiated in AI drug R&D. The development of “First in Disease” drugs has been its core strategy. Evergreen is fast-growing since the establishment. The company has developed 10 pipelines and half of them have been cleared by FDA for entry into clinical stages. With rich clinical experience and international registration experience, Evergreen have successfully and independently built an "end-to-end" AI platform, which suitable for effective operation in a highly regulated environment. Based on this platform, Evergreen have efficiently developed six new AI-designed Me-Only drugs. At present, a total of 5 pipelines have been cleared to enter the clinical stages in the United States: EG-001 idiopathic interstitial pneumonia pipeline and EG-009 COVID-19 cytokine storm (oral) pipeline have entered the phase I; Among them, EG-301 dry macular disease and EG-501 lupus erythematosus cognitive impairment drugs entered phase II; EG-007 endometrial cancer pipeline entered phase III.
Co-founder and Chairman of Evergreen Dr. Tom Du said: “We are honored to be one of the few AI-driven pharmaceutical companies in China to be recognized by the DeepTech. In the past three years, our team and pipeline development have achieved rapid growth. With the help of our unique AI platform, we have more and more pipelines successfully obtained FDA’s clearance to proceed into clinical stages. Evergreen is an innovative pharmaceutical company with “End-to-End” AI as one of its core technologies. We will continue to apply cutting-edge AI algorithms, quantum physics and advanced wet-lab technology, and combine them with clinical and regulatory experts' experience to extensively enable efficient research and development of innovative drugs. By doing so, we can bring more Me Only drugs to patients worldwide. "
About Digital Health Companies China 50
DeepTech is a full stack service platform focusing on data analyzing and publishing of emerging technology industries. It has in-depth cooperation with MIT Technology Review, which is a world-renowned, time-honored science and technology media company. The DeepTech list of “Digital Health Companies China 50” released in this event has comprehensively evaluated Chinese digital health companies from multiple dimensions, including technology model innovation, achievements of the past year, team and decision-making, industrial impact and ecological value, sustainable development and social value. Based on the rigorous evaluation and selection, top Chinese digital health companies have been listed. The“Digital Health Companies China 50” also sheds lights on the foundation and development opportunities of the current digital healthcare industry in China. The listing attests to the recognition of Evergreen Therapeutics’ scientific and technological value by the international scientific media.
